Tech-Driven Pharma Company TrialSpark Secures $156 Million In Series C Funding

TrialSpark announced it raised $156 million in Series C funding. Sam Altman and Lachy Groom led the funding round with participation from new and existing investors, including Sequoia Capital (Series A lead), Thrive Capital (Series B lead), Casdin Capital, Dragoneer, Section 32, John Doerr, Spark Capital, Felicis Ventures, Sound Ventures, Arrowmark, and previous investors.

Read the source article at Pulse 2.0
2021-10-10 04:09:37